You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameIbandronate
Accession NumberDB00710  (APRD00231, DB04635)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionIbandronate is a nitrogen-containing bisphosphonate in the same class as alendronate and risedronate. Ibandronate inhibits osteoclast-mediated bone resorption. All of the bisphosphonates prevent the breakdown of bone by bone cells called osteoclasts. In persons who are at high risk for osteoporosis, bisphosphonates not only result in increased amounts of bone and bone strength, they also reduce the risk of hip fractures and other bone fractures.
Structure
Thumb
Synonyms
Bondronat
Ibandronic Acid
External Identifiers
  • R484
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BondronatLiquid1 mgIntravenousHoffmann La Roche Limited2004-05-312006-05-17Canada
BonivaTablet, film coated150 mg/1OralGenentech, Inc.2002-07-15Not applicableUs
BonivaInjection, solution3 mg/3mLIntravenousGenentech, Inc.2011-06-01Not applicableUs
BonivaTablet, film coated150 mg/1OralPhysicians Total Care, Inc.2005-06-02Not applicableUs
BonvivaInjection, solution3 mgIntravenousRoche Registration Ltd.2004-02-23Not applicableEu
BonvivaTablet, film coated150 mgOralRoche Registration Ltd.2004-02-23Not applicableEu
BonvivaTablet, film coated150 mgOralRoche Registration Ltd.2004-02-23Not applicableEu
BonvivaInjection, solution3 mgIntravenousRoche Registration Ltd.2004-02-23Not applicableEu
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
IasibonInjection, solution, concentrate6 mgIntravenousPharmathen S.A.2011-01-21Not applicableEu
IasibonTablet, film coated50 mgOralPharmathen S.A.2011-01-21Not applicableEu
IasibonTablet, film coated50 mgOralPharmathen S.A.2011-01-21Not applicableEu
IasibonInjection, solution, concentrate6 mgIntravenousPharmathen S.A.2011-01-21Not applicableEu
IasibonTablet, film coated50 mgOralPharmathen S.A.2011-01-21Not applicableEu
IasibonTablet, film coated50 mgOralPharmathen S.A.2011-01-21Not applicableEu
IasibonInjection, solution, concentrate6 mgIntravenousPharmathen S.A.2011-01-21Not applicableEu
IasibonInjection, solution, concentrate1 mgIntravenousPharmathen S.A.2011-01-21Not applicableEu
IasibonTablet, film coated50 mgOralPharmathen S.A.2011-01-21Not applicableEu
IasibonInjection, solution, concentrate2 mgIntravenousPharmathen S.A.2011-01-21Not applicableEu
Ibandronate SodiumTablet, film coated150 mg/1OralApotex Corp2012-03-19Not applicableUs
Ibandronate SodiumTablet150 mg/1OralWatson Laboratories, Inc.2012-03-20Not applicableUs
Ibandronate SodiumTablet150 mg/1OralAlvogen Inc.2014-05-01Not applicableUs
Ibandronate SodiumTablet, film coated150 mg/1OralGolden State Medical Supply, Inc.2016-02-05Not applicableUs
Ibandronate SodiumInjection, solution3 mg/3mLIntravenousSun Pharmaceutical Industries Limited2014-02-15Not applicableUs
Ibandronate SodiumInjection, solution3 mg/3mLIntravenousHeritage Pharmaceuticals Inc.2014-09-04Not applicableUs
Ibandronate SodiumTablet150 mg/1OralDr. Reddy's Laboratories Limited2012-06-21Not applicableUs
Ibandronate SodiumInjection, solution3 mg/3mLIntravenousMylan Institutional LLC2014-09-02Not applicableUs
Ibandronate SodiumTablet, film coated150 mg/1OralAurobindo Pharma Limited2016-03-11Not applicableUs
Ibandronate SodiumInjection, solution3 mg/3mLIntravenousSagent Pharmaceuticals2014-09-02Not applicableUs
Ibandronate SodiumInjection, solution3 mg/3mLIntravenousAuro Medics Pharma Llc2015-08-19Not applicableUs
Ibandronate SodiumInjection3 mg/3mLIntravenousApotex Corp.2016-01-13Not applicableUs
Ibandronate SodiumTablet150 mg/1OralAv Kare, Inc.2013-12-042016-10-13Us
Ibandronate SodiumInjection, solution3 mg/3mLIntravenousAccord Healthcare Inc.2016-08-15Not applicableUs
Ibandronic Acid AccordInjection, solution, concentrate6 mgIntravenousAccord Healthcare Ltd2012-11-19Not applicableEu
Ibandronic Acid AccordInjection, solution3 mgIntravenousAccord Healthcare Ltd2012-11-19Not applicableEu
Ibandronic Acid AccordInjection, solution, concentrate6 mgIntravenousAccord Healthcare Ltd2012-11-19Not applicableEu
Ibandronic Acid AccordInjection, solution, concentrate6 mgIntravenousAccord Healthcare Ltd2012-11-19Not applicableEu
Ibandronic Acid AccordInjection, solution, concentrate2 mgIntravenousAccord Healthcare Ltd2012-11-19Not applicableEu
Ibandronic Acid AccordInjection, solution3 mgIntravenousAccord Healthcare Ltd2012-11-19Not applicableEu
Ibandronic Acid SandozTablet, film coated50 mgOralSandoz Gmb H2011-07-26Not applicableEu
Ibandronic Acid SandozTablet, film coated50 mgOralSandoz Gmb H2011-07-26Not applicableEu
Ibandronic Acid SandozTablet, film coated50 mgOralSandoz Gmb H2011-07-26Not applicableEu
Ibandronic Acid SandozTablet, film coated50 mgOralSandoz Gmb H2011-07-26Not applicableEu
Ibandronic Acid SandozTablet, film coated50 mgOralSandoz Gmb H2011-07-26Not applicableEu
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BondenzaTablet, film coated150 mgOralRoche Registration Ltd.2004-02-23Not applicableEu
BondenzaTablet, film coated150 mgOralRoche Registration Ltd.2004-02-23Not applicableEu
BondenzaInjection, solution3 mgIntravenousRoche Registration Ltd.2004-02-23Not applicableEu
BondenzaInjection, solution3 mgIntravenousRoche Registration Ltd.2004-02-23Not applicableEu
International Brands
NameCompany
ADRONiLNot Available
BonvivaNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Ibandronate sodium
138926-19-9
Thumb
  • InChI Key: LXLBEOAZMZAZND-UHFFFAOYNA-M
  • Monoisotopic Mass: 341.076919762
  • Average Mass: 341.2108
DBSALT000246
Categories
UNIIUMD7G2653W
CAS number114084-78-5
WeightAverage: 319.2289
Monoisotopic: 319.094975119
Chemical FormulaC9H23NO7P2
InChI KeyMPBVHIBUJCELCL-UHFFFAOYSA-N
InChI
InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)
IUPAC Name
{1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl}phosphonic acid
SMILES
CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O
Pharmacology
IndicationFor the treatment and prevention of osteoporosis in postmenopausal women.
Structured Indications
PharmacodynamicsIbandronate is a nitrogen-containing bisphosphonate in the same class as alendronate and risedronate. Ibandronate inhibits osteoclast-mediated bone resorption. All of the bisphosphonates prevent the breakdown of bone by bone cells called osteoclasts. In persons who are at high risk for osteoporosis, bisphosphonates not only result in increased amounts of bone and bone strength, they also reduce the risk of hip fractures and other bone fractures.
Mechanism of actionThe action of ibandronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate and zoledronate) appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting farnesyl pyrophosphate (FPP) synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.
TargetKindPharmacological actionActionsOrganismUniProt ID
Farnesyl pyrophosphate synthaseProteinyes
inhibitor
HumanP14324 details
HydroxylapatiteSmall moleculeyes
antagonist
Humannot applicabledetails
Related Articles
AbsorptionPoorly absorbed (mean bioavailability following a 2.5 mg oral dose is about 0.6% compared to intravenous dosing). Absorption is impaired by any kind of food or drink other than plain water.
Volume of distribution
  • 90 L
Protein binding90.9 to 99.5% over an ibandronate concentration range of 2 to 10 ng/mL
Metabolism

No evidence of ibandronate being metabolized in humans.

Route of eliminationIbandronate is eliminated by renal excretion. Unabsorbed ibandronate is eliminated unchanged in the feces.
Half life10-60 hours
Clearance
  • 84 to 160 mL/min [IV administration]
ToxicityLD50 = 811 mg/kg (rat, oral), side effects include bronchitis, pneumonia and urinary tract infections.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Ibandronate Action PathwayDrug actionSMP00079
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Ibandronate.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Acetovanillone is combined with Ibandronate.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ibandronate.Approved, Vet Approved
AclarubicinAclarubicin may increase the hypocalcemic activities of Ibandronate.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Ibandronate.Approved
Aluminum hydroxideThe serum concentration of Ibandronate can be decreased when it is combined with Aluminum hydroxide.Approved
Aluminum phosphateThe serum concentration of Ibandronate can be decreased when it is combined with Aluminum phosphate.Approved
AmikacinAmikacin may increase the hypocalcemic activities of Ibandronate.Approved, Vet Approved
AmiodaroneIbandronate may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmrubicinAmrubicin may increase the hypocalcemic activities of Ibandronate.Approved, Investigational
AnagrelideIbandronate may increase the QTc-prolonging activities of Anagrelide.Approved
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Ibandronate.Investigational
annamycinannamycin may increase the hypocalcemic activities of Ibandronate.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Ibandronate.Approved
ApramycinApramycin may increase the hypocalcemic activities of Ibandronate.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Ibandronate.Approved, Investigational
ArbekacinArbekacin may increase the hypocalcemic activities of Ibandronate.Approved
Arsenic trioxideIbandronate may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherIbandronate may increase the QTc-prolonging activities of Artemether.Approved
AsenapineIbandronate may increase the QTc-prolonging activities of Asenapine.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Ibandronate.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Ibandronate.Approved
AzithromycinIbandronate may increase the QTc-prolonging activities of Azithromycin.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Ibandronate.Approved, Investigational
BedaquilineIbandronate may increase the QTc-prolonging activities of Bedaquiline.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Ibandronate.Withdrawn
Betulinic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Ibandronate.Investigational
Bismuth SubcitrateThe serum concentration of Ibandronate can be decreased when it is combined with Bismuth Subcitrate.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Ibandronate.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Ibandronate.Investigational
CalciumThe serum concentration of Ibandronate can be decreased when it is combined with Calcium.Nutraceutical
Calcium AcetateThe serum concentration of Ibandronate can be decreased when it is combined with Calcium Acetate.Approved
Calcium carbonateThe serum concentration of Ibandronate can be decreased when it is combined with Calcium carbonate.Approved
Calcium ChlorideThe serum concentration of Ibandronate can be decreased when it is combined with Calcium Chloride.Approved
Calcium citrateThe serum concentration of Ibandronate can be decreased when it is combined with Calcium citrate.Approved
Calcium glubionateThe serum concentration of Ibandronate can be decreased when it is combined with Calcium glubionate.Approved
Calcium GluceptateThe serum concentration of Ibandronate can be decreased when it is combined with Calcium Gluceptate.Approved
Calcium gluconateThe serum concentration of Ibandronate can be decreased when it is combined with Calcium gluconate.Approved, Vet Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Ibandronate.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Ibandronate.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Ibandronate.Approved, Investigational
CeritinibIbandronate may increase the QTc-prolonging activities of Ceritinib.Approved
ChloroquineIbandronate may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorpromazineIbandronate may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
CiprofloxacinIbandronate may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideIbandronate may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramIbandronate may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinIbandronate may increase the QTc-prolonging activities of Clarithromycin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Ibandronate.Approved
ClozapineIbandronate may increase the QTc-prolonging activities of Clozapine.Approved
CrizotinibIbandronate may increase the QTc-prolonging activities of Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Ibandronate.Investigational
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Ibandronate.Investigational
DaunorubicinDaunorubicin may increase the hypocalcemic activities of Ibandronate.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Ibandronate is combined with Deferasirox.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Ibandronate.Approved, Vet Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Ibandronate.Approved
DihydrostreptomycinDihydrostreptomycin may increase the hypocalcemic activities of Ibandronate.Vet Approved
DisopyramideIbandronate may increase the QTc-prolonging activities of Disopyramide.Approved
DofetilideIbandronate may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronIbandronate may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneIbandronate may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoxorubicinDoxorubicin may increase the hypocalcemic activities of Ibandronate.Approved, Investigational
DronedaroneIbandronate may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolIbandronate may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Ibandronate.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Ibandronate.Investigational
E6201The risk or severity of adverse effects can be increased when E6201 is combined with Ibandronate.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ebselen is combined with Ibandronate.Investigational
EliglustatIbandronate may increase the QTc-prolonging activities of Eliglustat.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Ibandronate.Approved
EpirubicinEpirubicin may increase the hypocalcemic activities of Ibandronate.Approved
ErythromycinIbandronate may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramIbandronate may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EsomeprazoleThe therapeutic efficacy of Ibandronate can be decreased when used in combination with Esomeprazole.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Ibandronate.Approved, Investigational
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Ibandronate.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Ibandronate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Ibandronate.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Ibandronate.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Ibandronate.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Ibandronate.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Ibandronate.Approved
Ferric CitrateThe serum concentration of Ibandronate can be decreased when it is combined with Ferric Citrate.Approved
FlecainideIbandronate may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Ibandronate.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Ibandronate.Vet Approved
FluoxetineIbandronate may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolIbandronate may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Ibandronate.Approved, Investigational
FramycetinFramycetin may increase the hypocalcemic activities of Ibandronate.Approved
Gadobenic acidIbandronate may increase the QTc-prolonging activities of Gadobenic acid.Approved
GemifloxacinIbandronate may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GeneticinGeneticin may increase the hypocalcemic activities of Ibandronate.Experimental
GentamicinGentamicin may increase the hypocalcemic activities of Ibandronate.Approved, Vet Approved
GENTAMICIN C1AGENTAMICIN C1A may increase the hypocalcemic activities of Ibandronate.Experimental
GoserelinIbandronate may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronIbandronate may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
HaloperidolIbandronate may increase the QTc-prolonging activities of Haloperidol.Approved
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Ibandronate.Investigational
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Ibandronate.Investigational
Hygromycin BHygromycin B may increase the hypocalcemic activities of Ibandronate.Vet Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Ibandronate.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Ibandronate.Withdrawn
IbutilideIbandronate may increase the QTc-prolonging activities of Ibutilide.Approved
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Ibandronate.Approved
IdarubicinIdarubicin may increase the hypocalcemic activities of Ibandronate.Approved
IloperidoneIbandronate may increase the QTc-prolonging activities of Iloperidone.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Ibandronate.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Ibandronate.Withdrawn
INNO-206INNO-206 may increase the hypocalcemic activities of Ibandronate.Investigational
Iron saccharateThe serum concentration of Ibandronate can be decreased when it is combined with Iron saccharate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Ibandronate.Withdrawn
KanamycinKanamycin may increase the hypocalcemic activities of Ibandronate.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Ibandronate.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Ibandronate.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Ibandronate.Approved
LansoprazoleThe therapeutic efficacy of Ibandronate can be decreased when used in combination with Lansoprazole.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Ibandronate.Approved, Investigational
LenvatinibIbandronate may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideIbandronate may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevofloxacinIbandronate may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Ibandronate.Investigational
LopinavirIbandronate may increase the QTc-prolonging activities of Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Ibandronate.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Ibandronate.Approved
LumefantrineIbandronate may increase the QTc-prolonging activities of Lumefantrine.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Ibandronate.Approved, Investigational
Magnesium carbonateThe serum concentration of Ibandronate can be decreased when it is combined with Magnesium carbonate.Approved
Magnesium hydroxideThe serum concentration of Ibandronate can be decreased when it is combined with Magnesium hydroxide.Approved
Magnesium oxideThe serum concentration of Ibandronate can be decreased when it is combined with Magnesium oxide.Approved
Magnesium salicylateThe serum concentration of Ibandronate can be decreased when it is combined with Magnesium salicylate.Approved
Magnesium SulfateThe serum concentration of Ibandronate can be decreased when it is combined with Magnesium Sulfate.Approved, Vet Approved
Magnesium TrisilicateThe serum concentration of Ibandronate can be decreased when it is combined with Magnesium Trisilicate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Ibandronate.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ibandronate.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Ibandronate.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Ibandronate.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Ibandronate.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Ibandronate.Withdrawn
MethadoneIbandronate may increase the QTc-prolonging activities of Methadone.Approved
MetrizamideMetrizamide may increase the hypocalcemic activities of Ibandronate.Approved
MifepristoneMifepristone may increase the QTc-prolonging activities of Ibandronate.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Ibandronate.Investigational
MoxifloxacinIbandronate may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Ibandronate.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ibandronate.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Ibandronate.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Ibandronate.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Ibandronate.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Ibandronate.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Ibandronate.Investigational
NeamineNeamine may increase the hypocalcemic activities of Ibandronate.Experimental
NeomycinNeomycin may increase the hypocalcemic activities of Ibandronate.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Ibandronate.Approved
NetilmicinNetilmicin may increase the hypocalcemic activities of Ibandronate.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Ibandronate.Approved
NilotinibIbandronate may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Ibandronate.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Ibandronate.Investigational
OfloxacinIbandronate may increase the QTc-prolonging activities of Ofloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ibandronate.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Ibandronate.Approved
OmeprazoleThe therapeutic efficacy of Ibandronate can be decreased when used in combination with Omeprazole.Approved, Investigational, Vet Approved
OndansetronIbandronate may increase the QTc-prolonging activities of Ondansetron.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Ibandronate.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Ibandronate.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Ibandronate.Withdrawn
PaliperidoneIbandronate may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatIbandronate may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
PantoprazoleThe therapeutic efficacy of Ibandronate can be decreased when used in combination with Pantoprazole.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Ibandronate.Approved
ParomomycinParomomycin may increase the hypocalcemic activities of Ibandronate.Approved, Investigational
PazopanibIbandronate may increase the QTc-prolonging activities of Pazopanib.Approved
PentamidineIbandronate may increase the QTc-prolonging activities of Pentamidine.Approved
PerflutrenIbandronate may increase the QTc-prolonging activities of Perflutren.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Ibandronate.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ibandronate.Approved, Investigational
PimozideIbandronate may increase the QTc-prolonging activities of Pimozide.Approved
PirarubicinPirarubicin may increase the hypocalcemic activities of Ibandronate.Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Ibandronate.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Ibandronate.Approved, Investigational
PlicamycinPlicamycin may increase the hypocalcemic activities of Ibandronate.Approved, Withdrawn
PrimaquineIbandronate may increase the QTc-prolonging activities of Primaquine.Approved
ProcainamideIbandronate may increase the QTc-prolonging activities of Procainamide.Approved
PromazineIbandronate may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Ibandronate.Approved
PropafenoneIbandronate may increase the QTc-prolonging activities of Propafenone.Approved
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Ibandronate.Investigational
PuromycinPuromycin may increase the hypocalcemic activities of Ibandronate.Experimental
QuetiapineIbandronate may increase the QTc-prolonging activities of Quetiapine.Approved
QuinidineIbandronate may increase the QTc-prolonging activities of Quinidine.Approved
QuinineIbandronate may increase the QTc-prolonging activities of Quinine.Approved
RabeprazoleThe therapeutic efficacy of Ibandronate can be decreased when used in combination with Rabeprazole.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Ibandronate.Experimental, Investigational
RibostamycinRibostamycin may increase the hypocalcemic activities of Ibandronate.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Ibandronate.Investigational, Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Ibandronate.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Ibandronate.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Ibandronate.Approved
SaquinavirIbandronate may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Ibandronate.Approved, Investigational
SisomicinSisomicin may increase the hypocalcemic activities of Ibandronate.Investigational
SotalolIbandronate may increase the QTc-prolonging activities of Sotalol.Approved
SP1049CSP1049C may increase the hypocalcemic activities of Ibandronate.Investigational
SpectinomycinSpectinomycin may increase the hypocalcemic activities of Ibandronate.Approved, Vet Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Ibandronate.Investigational
StreptomycinStreptomycin may increase the hypocalcemic activities of Ibandronate.Approved, Vet Approved
StreptozocinStreptozocin may increase the hypocalcemic activities of Ibandronate.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ibandronate.Approved
SulfisoxazoleIbandronate may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Ibandronate.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Ibandronate.Approved, Withdrawn
TAK-390MRThe therapeutic efficacy of Ibandronate can be decreased when used in combination with TAK-390MR.Investigational
TelavancinIbandronate may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinIbandronate may increase the QTc-prolonging activities of Telithromycin.Approved
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Ibandronate.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Ibandronate.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Ibandronate.Approved
TetrabenazineIbandronate may increase the QTc-prolonging activities of Tetrabenazine.Approved
ThioridazineIbandronate may increase the QTc-prolonging activities of Thioridazine.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Ibandronate.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Ibandronate.Investigational
TobramycinTobramycin may increase the hypocalcemic activities of Ibandronate.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Ibandronate.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Ibandronate.Approved
ToremifeneIbandronate may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Ibandronate.Approved, Investigational
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Ibandronate.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Ibandronate.Investigational, Withdrawn
ValrubicinValrubicin may increase the hypocalcemic activities of Ibandronate.Approved
VandetanibIbandronate may increase the QTc-prolonging activities of Vandetanib.Approved
VemurafenibIbandronate may increase the QTc-prolonging activities of Vemurafenib.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Ibandronate.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Ibandronate.Approved, Investigational, Withdrawn
ZiprasidoneIbandronate may increase the QTc-prolonging activities of Ziprasidone.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Ibandronate.Withdrawn
ZorubicinZorubicin may increase the hypocalcemic activities of Ibandronate.Experimental
ZuclopenthixolIbandronate may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take on an empty stomach. All foods markedly reduce (up to 90%) ibandronate bioavailabilty. Take with plain water (not mineralized) at least 1 hour before any food. Bioavailability and effect on bone density are both impaired if the patient eats or drinks in less than 1 hour after taking this product. Drink a large glass of water and stay in an upright position for at least 60 minutes after taking this product.
References
Synthesis Reference

Revital Lifshitz-Liron, Thomas Bayer, Judith Aronhime, Michael Pinchasov, “Solid and crystalline ibandronate sodium and processes for preparation thereof.” U.S. Patent US20070179119, issued August 02, 2007.

US20070179119
General References
  1. Epstein S, Zaidi M: Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis. Bone. 2005 Oct;37(4):433-40. [PubMed:16046205 ]
External Links
ATC CodesM05BA06
AHFS Codes
  • 92:00
PDB Entries
FDA labelDownload (296 KB)
MSDSDownload (16 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9664
Blood Brain Barrier-0.5229
Caco-2 permeable-0.6012
P-glycoprotein substrateSubstrate0.6888
P-glycoprotein inhibitor INon-inhibitor0.8195
P-glycoprotein inhibitor IINon-inhibitor0.9838
Renal organic cation transporterNon-inhibitor0.9092
CYP450 2C9 substrateNon-substrate0.8376
CYP450 2D6 substrateNon-substrate0.7863
CYP450 3A4 substrateNon-substrate0.5504
CYP450 1A2 substrateNon-inhibitor0.832
CYP450 2C9 inhibitorNon-inhibitor0.8159
CYP450 2D6 inhibitorNon-inhibitor0.8987
CYP450 2C19 inhibitorNon-inhibitor0.8045
CYP450 3A4 inhibitorNon-inhibitor0.8901
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9945
Ames testNon AMES toxic0.6527
CarcinogenicityNon-carcinogens0.683
BiodegradationNot ready biodegradable0.8346
Rat acute toxicity2.4278 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6061
hERG inhibition (predictor II)Non-inhibitor0.6622
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Hoffmann la roche inc
Packagers
Dosage forms
FormRouteStrength
Injection, solutionIntravenous3 mg
Tablet, film coatedOral150 mg
LiquidIntravenous1 mg
Injection, solutionIntravenous3 mg/3mL
Tablet, film coatedOral150 mg/1
Injection, solution, concentrateIntravenous1 mg
Injection, solution, concentrateIntravenous2 mg
Injection, solution, concentrateIntravenous6 mg
Tablet, film coatedOral50 mg
InjectionIntravenous3 mg/3mL
TabletOral150 mg/1
Prices
Unit descriptionCostUnit
Boniva 3 mg/3ml Kit Box524.22USD box
Boniva 3 mg/3 ml syringe504.06USD syringe
Boniva 3 150 mg tablet Disp Pack388.93USD disp
Boniva 150 mg tablet124.66USD tablet
Boniva 2.5 mg tablet4.16USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2346662 No2006-05-092019-10-01Canada
US4927814 No1995-03-172012-03-17Us
US6143326 No1997-04-212017-04-21Us
US6294196 No1999-10-072019-10-07Us
US7192938 No2003-05-062023-05-06Us
US7410957 No2003-05-062023-05-06Us
US7718634 No2003-05-062023-05-06Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityFreely solubleNot Available
logP-2.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility13.4 mg/mLALOGPS
logP0.26ALOGPS
logP-2.5ChemAxon
logS-1.4ALOGPS
pKa (Strongest Acidic)0.66ChemAxon
pKa (Strongest Basic)9.93ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area138.53 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity71.16 m3·mol-1ChemAxon
Polarizability29.51 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as bisphosphonates. These are organic compounds containing two phosphonate groups linked together through a carbon atoms.
KingdomOrganic compounds
Super ClassOrganophosphorus compounds
ClassOrganic phosphonic acids and derivatives
Sub ClassBisphosphonates
Direct ParentBisphosphonates
Alternative Parents
Substituents
  • Bisphosphonate
  • Organophosphonic acid
  • 1,3-aminoalcohol
  • Tertiary aliphatic amine
  • Tertiary amine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Poly(a) rna binding
Specific Function:
Key enzyme in isoprenoid biosynthesis which catalyzes the formation of farnesyl diphosphate (FPP), a precursor for several classes of essential metabolites including sterols, dolichols, carotenoids, and ubiquinones. FPP also serves as substrate for protein farnesylation and geranylgeranylation. Catalyzes the sequential condensation of isopentenyl pyrophosphate with the allylic pyrophosphates, d...
Gene Name:
FDPS
Uniprot ID:
P14324
Molecular Weight:
48275.03 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Chapurlat RD, Delmas PD: Drug insight: Bisphosphonates for postmenopausal osteoporosis. Nat Clin Pract Endocrinol Metab. 2006 Apr;2(4):211-9; quiz following 238. [PubMed:16932286 ]
  3. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001 Feb;296(2):235-42. [PubMed:11160603 ]
  4. Rondeau JM, Bitsch F, Bourgier E, Geiser M, Hemmig R, Kroemer M, Lehmann S, Ramage P, Rieffel S, Strauss A, Green JR, Jahnke W: Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. ChemMedChem. 2006 Feb;1(2):267-73. [PubMed:16892359 ]
Kind
Small molecule
Organism
Human
Pharmacological action
yes
Actions
antagonist
References
  1. Jahnke W, Henry C: An in vitro assay to measure targeted drug delivery to bone mineral. ChemMedChem. 2010 May 3;5(5):770-6. doi: 10.1002/cmdc.201000016. [PubMed:20209564 ]
  2. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH: Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006 May;38(5):617-27. Epub 2005 Jul 20. [PubMed:16046206 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 08, 2016 11:11